DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
DexCom's earnings call indicates positive sentiment with raised revenue guidance, product launches, and international expansion plans. Despite lowered gross profit margin guidance, the company plans to offset this through operating expense leverage. The Q&A section reveals strong engagement in the basal segment, positive early results for the G7 product, and expanding coverage for type 2 diabetes users. While some uncertainties remain, such as CMS coverage timelines, the overall outlook with new product launches and international expansion is optimistic, suggesting a positive stock price reaction.
Key Financial Performance
Worldwide Revenue $1.26 billion for Q4 2025, compared to $1.11 billion for Q4 2024, representing growth of 13% on a reported basis and 12% on an organic basis. The growth was driven by strong new customer demand and encouraging sell-through trends.
U.S. Revenue $892 million for Q4 2025, compared to $803 million for Q4 2024, representing an increase of 11%. This growth correlated with the broader G7 15 Day product launch, which generated significant interest.
International Revenue $368 million for Q4 2025, representing an 18% increase compared to Q4 2024. Organic growth was 15%. Growth was particularly strong in markets like Germany, the UK, and France, with France benefiting from significant type 2 access expansion.
Gross Profit $799.8 million for Q4 2025, or 63.5% of revenue, compared to 59.4% of revenue in Q4 2024. The improvement was due to reduced freight expenses and better supply chain performance.
Operating Expenses $468.3 million for Q4 2025, compared to $451.7 million in Q4 2024. The increase was attributed to investments in sales, innovation, and operational support.
Operating Income $331.5 million for Q4 2025, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024. This improvement was driven by higher gross margins and operational efficiencies.
Adjusted EBITDA $422.2 million for Q4 2025, or 33.5% of revenue, compared to $300.1 million, or 27.0% of revenue, in Q4 2024. The increase was due to improved gross margins and operational performance.
Net Income $265.1 million for Q4 2025, or $0.68 per share. This reflects strong revenue growth and operational improvements.
Cash and Cash Equivalents Approximately $2 billion as of the end of Q4 2025. This strong cash position allowed for settling $1.2 billion in convertible notes and repurchasing $300 million of stock.
Free Cash Flow Surpassed $1 billion for the first time in 2025, reflecting strong financial performance and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DexCom G7 15 Day system: Broad rollout in the U.S. with excellent initial feedback. Features include longer wear time, reduced sensor changes, and a new algorithm for improved accuracy.
My DexCom Account: A newly launched digital support system streamlining customer support and saving time.
DexCom Smart Basal: Early access launch for managing type 2 diabetes with basal insulin. Offers personalized dosing, simplifies workflows, and improves outcomes.
DexCom Direct EHR Integration: Live or onboarding at over 160 health systems, providing quick and easy connection to customer CGM data.
Stelo Nutrition Database: Comprehensive database for smart food logging, offering detailed macronutrient breakdowns.
New Patch Technology: Received clearance for technology improving sensor survival on G7 systems, including G7 15 Day.
International Revenue Growth: 18% growth in Q4 2025, with strong performance in Germany, the UK, and France. France benefited from type 2 access expansion.
International Market Expansion: Plans to add Stelo and a new CGM system in 2026 to expand access in international markets.
Revenue Growth: 13% growth in Q4 2025, with full-year revenue exceeding guidance.
Manufacturing and Logistics: Improved inventory levels, reestablished efficient shipping routes, and strengthened supply chain performance.
Gross Margin Improvement: Sequential improvement of over 200 basis points in Q4 2025 due to better freight expenses and supply chain performance.
Customer Experience Focus: Enhancing customer satisfaction through innovations like My DexCom Account, Smart Basal, and new patch technology.
International Market Share Expansion: Focus on broader DexCom awareness and CGM access globally, with potential for international markets to surpass U.S. market size.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Performance: The company faced supply chain challenges in 2025, including sensor deployment issues and inefficiencies in shipping routes. Although improvements were made, these challenges could reoccur and impact operations.
Product Launch Risks: The success of the G7 15 Day product launch is critical, and any issues with product performance or customer experience could negatively affect market perception and sales.
International Market Expansion: Expanding into international markets involves risks such as regulatory hurdles, market-specific challenges, and the need for tailored product offerings, which could impact growth.
Manufacturing and Logistics: The company is investing in a new manufacturing facility in Ireland, which involves risks related to operational setup, cost overruns, and timely execution.
Economic and Coverage Landscape: The guidance assumes no significant changes in the coverage landscape or economic conditions. Any adverse changes could impact revenue and growth projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: DexCom anticipates total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year.
Gross Profit Margin: The company expects full year non-GAAP gross profit margin to be in the range of 63% to 64%, with improvements driven by lower freight expenses, additional manufacturing efficiencies, and the growing contribution from the G7 15 Day product.
Operating Profit Margin: Non-GAAP operating profit margin is projected to be approximately 22% to 23% for 2026.
Adjusted EBITDA Margin: DexCom expects an adjusted EBITDA margin of approximately 30% to 31% for 2026.
Product Launches and Advancements: Incremental growth is expected from Stelo and new product advancements across the platform, including the G7 15 Day system and other innovations.
Medicare Coverage Expansion: The company anticipates broader global coverage, including expectations for Medicare coverage for the type 2 non-insulin population.
Manufacturing Facility: DexCom plans to launch its Ireland manufacturing facility late in 2026 to support global sales and innovation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase: During the fourth quarter, DexCom repurchased $300 million of stock in the open market. This activity was part of their broader financial strategy and was supported by their strong cash position, which remains robust even after settling $1.2 billion of expiring convertible notes in cash.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Where do you see the existing legacy and core markets going in the coming years, particularly with non-intensive type 2 coverage?
A:Jacob Leach stated that the company is in the early stages of addressing the global diabetes problem. He highlighted the significant outcomes their technology provides across all patient segments, including type 1, type 2 insulin users, and type 2 non-insulin users. He mentioned that Medicare coverage expansion could unlock access for almost 12 million people, creating a tremendous growth opportunity. Internationally, the market is expected to grow larger than the U.S. over time, although coverage typically lags behind the U.S.
Q:Do you agree with your competitor's estimate that CMS coverage for type 2 non-insulin users will come in the first half of 2026?
A:Jacob Leach did not directly confirm the timeline but mentioned that they are working with CMS and highlighted the ADA's updated guidelines recommending CGM for type 2 non-insulin users. He also discussed their ongoing randomized controlled trial (RCT) for this group, with results expected mid-year, which could support Medicare coverage decisions.
Q:How should we think about the rollout of the 15 Day product and its impact on margins and international growth?
A:Jereme Sylvain explained that the 15 Day product is expected to contribute to margins over time, with more significant contributions in future years as the base converts. He noted that the 15 Day platform will be the foundation for launching new products and entering emerging markets. Jacob Leach added that the 15 Day product has received positive feedback for its accuracy and reliability, and it will be extended globally.
Q:What are you spending on after such a great year of expense control, and how does this impact the 2026 outlook?
A:Jereme Sylvain mentioned investments in the Ireland manufacturing facility, including hiring, training, and validation samples, as a significant expense. These costs will shift from OpEx to COGS once the facility is operational in Q4 2026. He emphasized that the company is still achieving leverage, with gross margin improvements doing most of the work in 2026.
Q:How are you thinking about utilization trends, particularly for basal and non-insulin type 2 users?
A:Jacob Leach stated that utilization rates for type 1 and type 2 insulin users remain stable at 85%-90%. For basal users, utilization is around 80%-85%, consistent with clinical trial results. Early data from a registry of type 2 non-insulin users shows similar utilization rates to basal users, indicating strong engagement when coverage is available.
Q:What is assumed in the 2026 revenue outlook regarding new patient dynamics and operational factors?
A:Jereme Sylvain explained that the 2026 revenue outlook assumes a starting point of 20% patient base growth, with additional contributions from price and mix. He noted that record new patient additions are not required to hit the low end of guidance but would be needed for the high end. The guidance assumes no significant changes in coverage.
Q:What is driving the strengthening U.S. sensor uptake trends in Q4 and into Q1?
A:Jereme Sylvain attributed the improvement to reduced sensor deployment issues, the launch of the 15 Day product, and increased physician awareness of coverage changes for non-insulin users. He also noted stable retention rates and strong user experiences as contributing factors.
Q:How should we think about pricing dynamics with the potential Medicare unlock for type 2 non-insulin users?
A:Jereme Sylvain explained that pricing for Medicare is typically handled through competitive bidding, with no immediate changes expected. He noted that the company is building capacity in anticipation of Medicare coverage and expects the competitive bidding process to influence pricing starting in 2028.
Q:How do you plan to close the $2 billion revenue gap between U.S. and international markets?
A:Jacob Leach highlighted opportunities to expand within existing international markets and enter new ones. He emphasized the need to generate evidence, drive awareness, and tailor the product portfolio to different market needs. Jereme Sylvain added that the timeline for closing the gap is more than five years, given the strong growth potential in the U.S. and the need to enter many new markets.
Q:What has been the hurdle to deeper adoption in the basal segment, and how will Smart Basal help?
A:Jacob Leach acknowledged that basal adoption has been slower but noted that Smart Basal is designed to improve the user experience and outcomes for basal insulin users. The company is piloting the technology in clinics to refine workflows and drive adoption.
Q:Why does the 2026 gross margin guide not fully recover the one-time impacts from 2025?
A:Jereme Sylvain clarified that the one-time impacts from 2025 were slightly overstated in the question. He noted that improvements in gross margin will be offset by costs associated with the Ireland facility coming online in Q4 2026, which will temporarily lower gross margins.
Q:What is the contribution of Stelo to 2025 results, and what is expected in 2026?
A:Jereme Sylvain reported $130 million in Stelo revenue for 2025 and expects it to contribute about 1 point to growth in 2026. Jacob Leach added that Stelo is gaining traction among type 2 non-insulin users and serves as a pathway to transition these users to G7 as coverage expands.
Q:What is left in the software innovation pipeline, and do you need clinical validation for new features?
A:Jacob Leach stated that there is significant potential for software innovation to enhance the user experience and drive outcomes. He emphasized the importance of clinical validation and real-world evidence to support new features. Jereme Sylvain added that the company is exploring ways to bring innovation to users more quickly while adhering to regulatory requirements.
Q:What are the early results and rebate dynamics for the G7 15 Day product?
A:Jacob Leach reported strong early results for the G7 15 Day product, with sensor survival consistent with clinical studies. He noted that a new adhesive patch will further improve performance. Jereme Sylvain stated that the G7 15 Day product is priced the same as the 10 Day version, with no expected changes in rebate trends.
Q:What is the expected revenue cadence for 2026, particularly for Q1?
A:Jereme Sylvain indicated that Q1 2026 revenue is expected to decline 6%-7% sequentially from Q4 2025, reflecting reduced seasonality as more business shifts to the pharmacy channel. This is slightly less than the 7%-8% decline observed in the prior year.
Q:What is the current status of coverage for type 2 non-insulin users, and what is the cadence for unlocking more lives?
A:Jereme Sylvain reported that coverage for type 2 non-insulin users has expanded to about 6.5 million lives, up from 6 million. The company continues to work on adding more plans and expects to provide updates throughout the year.
Q:Review of Unclear Management Responses
A:Management avoided directly confirming the timeline for CMS coverage for type 2 non-insulin users, instead emphasizing ongoing efforts and the importance of their randomized controlled trial. Additionally, they did not provide a specific timeline for closing the $2 billion revenue gap between U.S. and international markets, only stating that it would take more than five years.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI customer
Account support
CEO area
CEO month
CEO way
CGM EHR
CGM access
CGM category
CGM product
CGM system
Day detail
Day hand
Day margin
Day product
Day system
Day type
DexCom Day
DexCom Direct
DexCom awareness
DexCom chapter
DexCom month
DexCom privilege
Direct EHR
EHR Integration
EHR platform
Instructions
Mr
Sean Vice
accuracy
basal insulin
food
margin expansion
ocean
offering
opportunity market
prescribers
priority
product launch
product portfolio
role CEO
sell trend
supply chain
DXCM Transcript
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
Positive2-12
DexCom's earnings call indicates positive sentiment with raised revenue guidance, product launches, and international expansion plans. Despite lowered gross profit margin guidance, the company plans to offset this through operating expense leverage. The Q&A section reveals strong engagement in the basal segment, positive early results for the G7 product, and expanding coverage for type 2 diabetes users. While some uncertainties remain, such as CMS coverage timelines, the overall outlook with new product launches and international expansion is optimistic, suggesting a positive stock price reaction.
Novo Nordisk A/S (NOVO:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
DexCom, Inc. (DXCM) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call highlights strong financial performance with record EPS, increased cash reserves, and improved operational efficiency. Positive developments include resolved G7 issues, a successful limited launch of the 15-day sensor, and growth across type 2 markets. Despite some deceleration in Q4 2025, the company maintains optimistic growth projections for 2026. The raised 2025 revenue guidance and strategic focus on innovation and market expansion further support a positive outlook. However, some concerns remain due to the lack of specific 2026 guidance and vague responses in the Q&A.
DXCM Slides
DXCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
